Amyloid-beta aggregate (N-terminal epitope) (Aβ aggregate)

Amyloid-beta (Aβ) aggregates, specifically those exposing the N-terminal epitope, are central pathological features of Alzheimer's disease (AD) (Hardy & Higgins, 1992, Science). These aggregates exist in various forms, including soluble oligomers, protofibrils, and insoluble fibrils that constitute amyloid plaques (Soderberg et al., 2023, Nature Communications). The N-terminal region of the Aβ peptide (typically residues 1-16) becomes accessible in these aggregated states, making it a primary target for therapeutic monoclonal antibodies like lecanemab and aducanumab (Sevigny et al., 2016, Nature; van Dyck et al., 2023, NEJM). By binding to this epitope, drugs aim to neutralize neurotoxic soluble species and promote the clearance of existing deposits via microglial-mediated phagocytosis (Ostrowitzki et al., 2012, Archives of Neurology). This intervention is intended to slow cognitive decline by reducing the amyloid burden and subsequent downstream neurodegeneration (Mintun et al., 2021, NEJM). Clinical evidence suggests that targeting protofibrils and fibrils via this epitope can significantly alter the disease trajectory in early-stage patients (Budd Haeberlein et al., 2022, Journal of Prevention of Alzheimer's Disease). Safety monitoring for these therapies primarily focuses on amyloid-related imaging abnormalities (ARIA), which are thought to result from the clearance of vascular amyloid (Sperling et al., 2011, Alzheimer's & Dementia). Overall, the N-terminal epitope of Aβ aggregates represents a validated site for disease-modifying intervention in neurodegenerative proteinopathies.

Other names

Amyloid-beta protofibrilAmyloid-beta oligomerAmyloid-beta fibrilAβ aggregateSoluble amyloid-beta species

Monoclonal antibodies bind to the N-terminal epitope of amyloid-beta aggregates, facilitating their clearance through microglia-mediated phagocytosis and preventing the further accumulation of neurotoxic protofibrils and plaques (Sevigny et al., 2016, Nature; van Dyck et al., 2023, NEJM).